Leerink Keeps BioMarin (BMRN) at 'Outperform' Amid EMA Validation of Brineura MAA
Tweet Send to a Friend
Leerink affirms BioMarin (Nasdaq: BMRN) at Outperform with a price target of $127 after the company announced that the European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
